Pfizer Inc. and Medivation Inc. have entered into an agreement for development and commercialization of Dimebon. Dimebon is Medivation’s investigational drug to be used in the treatment of Alzheimer’s disease and Huntington’s disease, currently in Phase III of its trial involving patients with mild-to-moderate Alzheimer’s disease. The companies will share all U.S. development and commercialization expenses along with U.S. profits/losses with Pfizer assuming the larger share (60%). In addition, Medivation will co-promote Dimebon to specialty physicians in the U.S.